Alexander P, Roskams T, Van Steenbergen W, Peetermans W, Desmet V, Yap S H
Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium.
Acta Clin Belg. 1991;46(5):327-32. doi: 10.1080/17843286.1991.11718184.
Two patients who developed a severe but reversible cholestatic jaundice during and after treatment with an amoxicillin/clavulanic acid preparation (Augmentin) are described. The diagnosis of drug-induced intrahepatic cholestasis was based on the clinical course, biochemical pattern and on histological findings. Since amoxicillin alone does not induce liver injury, the combination of amoxicillin and clavulanic acid or clavulanic acid alone could be responsible for this adverse reaction, probably through a metabolic idiosyncrasy or a hypersensitivity mechanism. Although more than 100 cases of hepatotoxic reactions have been reported to the pharmaceutical company (Beecham Laboratories) and several reports have been published, the incidence of hepatotoxicity of this antibiotic is relatively rare, since this antibiotic has been widely used. However, recognition of this benign and reversible cholestatic syndrome is important to avoid unnecessary, expensive and invasive diagnostic procedures.
本文描述了两名患者,他们在使用阿莫西林/克拉维酸制剂(奥格门汀)治疗期间及之后出现了严重但可逆的胆汁淤积性黄疸。药物性肝内胆汁淤积的诊断基于临床病程、生化指标及组织学检查结果。由于单独使用阿莫西林不会引起肝损伤,阿莫西林与克拉维酸的组合或单独使用克拉维酸可能是导致这种不良反应的原因,可能是通过代谢特异反应或超敏反应机制。尽管制药公司(比彻姆实验室)已收到100多例肝毒性反应报告,且已有多篇报道发表,但由于该抗生素已被广泛使用,其肝毒性的发生率相对较低。然而,认识到这种良性且可逆的胆汁淤积综合征对于避免不必要、昂贵且具有侵入性的诊断程序很重要。